Logo 1 Logo 2

Clinical Trial Details

Trial ID: L5810
Source ID: NCT01455870
Associated Drug: Itca 650 60 Mcg/Day
Title: A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Type 2 Diabetes
Interventions: DRUG: ITCA 650 60 mcg/day|DRUG: sitagliptin
Outcome Measures: Primary: Change in HbA1c between Week 52 and Day 0, 52 weeks |
Sponsor/Collaborators: Sponsor: Intarcia Therapeutics
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE3
Enrollment: 535
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
Start Date: 2013-05
Completion Date: 2015-07
Results First Posted:
Last Update Posted: 2016-06-02
Locations: Birmingham, Alabama, 35235, United States|Chandler, Arizona, 85224, United States|Long Beach, California, 90807, United States|Los Angeles, California, 90017, United States|San Diego, California, 92101, United States|San Mateo, California, 94401, United States|Tustin, California, 92780, United States|Valley Village, California, 91607, United States|Walnut Creek, California, 94598, United States|Boca Raton, Florida, 33432, United States|Clearwater, Florida, 33765, United States|Coral Gables, Florida, 33134, United States|Miami, Florida, 33126, United States|North Miami Beach, Florida, 33162, United States|Pembroke Pines, Florida, 33026, United States|Canton, Georgia, 30114, United States|Chicago, Illinois, 60607, United States|Chicago, Illinois, 60634, United States|Avon, Indiana, 46123, United States|Franklin, Indiana, 46131, United States|Greenfield, Indiana, 46140, United States|Muncie, Indiana, 47304, United States|Valparaiso, Indiana, 46383, United States|Wichita, Kansas, 67205, United States|Wichita, Kansas, 67208, United States|Metairie, Louisiana, 70006, United States|Brockton, Massachusetts, 2301, United States|Traverse City, Michigan, 49684, United States|Troy, Michigan, 48098, United States|St. Louis, Missouri, 63110, United States|Billings, Montana, 59101, United States|Lincoln, Nebraska, 68510, United States|Las Vegas, Nevada, 89148, United States|Brooklyn, New York, 11218, United States|Endwell, New York, 13760, United States|Morehead City, North Carolina, 28557, United States|Winston-Salem, North Carolina, 27103, United States|Cincinnati, Ohio, 45227, United States|Kettering, Ohio, 45429, United States|Norman, Oklahoma, 73069, United States|Bend, Oregon, 97701, United States|Uniontown, Pennsylvania, 15401, United States|Memphis, Tennessee, 38119, United States|Corpus Christi, Texas, 78414, United States|Dallas, Texas, 75230, United States|Dallas, Texas, 75390, United States|Houston, Texas, 77083, United States|San Antonio, Texas, 78229, United States|Sugar Land, Texas, 77478, United States|Tomball, Texas, 77375, United States|Rijeka, 51000, Croatia|Hvidovre, 2650, Denmark|Bad Lauterberg im Harz, Niedersachsen, 37431, Germany|Riga, LV1002, Latvia
URL: https://clinicaltrials.gov/show/NCT01455870

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress